Based on our above finding that IGF1/IGF1R axis facilitated HOXA13 overexpression and CRC metastasis through transactivating ACLY and IGF1R, we hypothesized that whether the combination of ACLY and IGF1R inhibitors had a synergistic effect on CRC treatment. Here, HOXA13 is linked to colorectal carcinoma.